Post-earnings recap
Reported
Wed, May 9, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a loss of $0.10 per share, which was in line with expectations, but no revenue figures were disclosed. The stock rose by 1.19%, likely driven by investor confidence in their clinical pipeline and ongoing trials. The lack of revenue and guidance suggests that investors are focusing on long-term potential rather than short-term results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management conveyed a cautious optimism regarding their clinical programs. They emphasized the importance of their ongoing trials and the potential for future growth.
Management highlighted ongoing developments in their clinical trials.
They expressed confidence in their pipeline despite the lack of revenue.
The focus remains on advancing their lead product candidates.